Lorenzo Cipriano

Dr. Lorenzo Cipriano

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2023 in NeuroImage: Clinical
Verified
Journal Article
Open access
LCLorenzo Cipriano
Lorenzo Cipriano
ELEmahnuel Troisi Lopez
Emahnuel Troisi Lopez
MLMarianna Liparoti
Marianna Liparoti
RMRoberta Minino
Roberta Minino
ARAntonella Romano
Antonella Romano
PSPierpaolo Sorrentino
Pierpaolo Sorrentino
Brain connectome fingerprinting is progressively gaining ground in the field of brain network analysis. It represents a valid approach in assessing the subject-specific connectivity and, according to recent studies, in predicting clinical impairment in some neurodegenerative diseases. Nevertheless, its performance, and clinical utility, in the Multiple Sclerosis (MS) field has not yet been investigated. We conducted the Clinical Connectome Fingerprint (CCF) analysis on source-reconstructed magnetoencephalography signals in a cohort of 50 subjects: twenty-five MS patients and twenty-five healthy controls. All the parameters of identifiability, in the alpha band, were reduced in patients as compared to controls. These results implied a lower similarity between functional connectomes (FCs) of the same patient and a reduced homogeneity among FCs in the MS group. We also demonstrated that in MS patients, reduced identifiability was able to predict, fatigue level (assessed by the Fatigue Severity Scale). These results confirm the clinical usefulness of the CCF in both identifying MS patients and predicting clinical impairment. We hope that the present study provides future prospects for treatment personalization on the basis of individual brain connectome.

1 December 2021 in Cortex
Verified
Journal Article
Closed access
DSDario Saracino
Dario Saracino
AGAmandine Géraudie
Amandine Géraudie
ARAnne M. Remes
Anne M. Remes
SFSophie Ferrieux
Sophie Ferrieux
MNMarie Noguès-Lassiaille
Marie Noguès-Lassiaille
DWDavid Wallon
David Wallon

1 March 2024 in Brain Communications
Verified
Journal Article
Open access
PDF file
LCLorenzo Cipriano
Lorenzo Cipriano
RMRoberta Minino
Roberta Minino
MLMarianna Liparoti
Marianna Liparoti
APArianna Polverino
Arianna Polverino
ARAntonella Romano
Antonella Romano
ELEmahnuel Troisi Lopez
Emahnuel Troisi Lopez
Large-scale brain activity has long been investigated under the erroneous assumption of stationarity. Nowadays, we know that resting-state functional connectivity is characterized by aperiodic, scale-free bursts of activity (i.e. neuronal avalanches) that intermittently recruit different brain regions. These different patterns of activity represent a measure of brain flexibility, whose reduction has been found to predict clinical impairment in multiple neurodegenerative diseases such as Parkinson’s disease, amyotrophic lateral sclerosis and Alzheimer’s disease. Brain flexibility has been recently found increased in multiple sclerosis, but its relationship with clinical disability remains elusive. Also, potential differences in brain dynamics according to the multiple sclerosis clinical phenotypes remain unexplored so far. We performed a brain dynamics study quantifying brain flexibility utilizing the ‘functional repertoire’ (i.e. the number of configurations of active brain areas) through source reconstruction of magnetoencephalography signals in a cohort of 25 multiple sclerosis patients (10 relapsing–remitting multiple sclerosis and 15 secondary progressive multiple sclerosis) and 25 healthy controls. Multiple sclerosis patients showed a greater number of unique reconfigurations at fast time scales as compared with healthy controls. This difference was mainly driven by the relapsing–remitting multiple sclerosis phenotype, whereas no significant differences in brain dynamics were found between secondary progressive multiple sclerosis and healthy controls. Brain flexibility also showed a different predictive power on clinical disability according to the multiple sclerosis type. For the first time, we investigated brain dynamics in multiple sclerosis patients through high temporal resolution techniques, unveiling differences in brain flexibility according to the multiple sclerosis phenotype and its relationship with clinical disability.

3 May 2025 in Human Brain Mapping
Verified
Journal Article
Open access
CMC. Mazzara
C. Mazzara
AZA. Ziaeemehr
A. Ziaeemehr
ELEmahnuel Troisi Lopez
Emahnuel Troisi Lopez
LCLorenzo Cipriano
Lorenzo Cipriano
MAM. Angiolelli
M. Angiolelli
PSPierpaolo Sorrentino
Pierpaolo Sorrentino
Multiple sclerosis (MS) is a clinically heterogeneous, multifactorial autoimmune disorder affecting the central nervous system. Structural damage to the myelin sheath, resulting in the consequent slowing of the conduction velocities, is a key pathophysiological mechanism. In fact, the conduction velocities are closely related to the degree of myelination, with thicker myelin sheaths associated to higher conduction velocities. However, how the intensity of the structural lesions of the myelin translates to slowing of nerve conduction delays is not known. In this work, we use large‐scale brain models and Bayesian model inversion to estimate how myelin lesions translate to longer conduction delays across the damaged tracts. A cohort of 38 subjects (20 healthy and 18 with MS) underwent MEG recordings during an eyes‐closed resting‐state condition, along with MRI acquisitions and detailed white matter tractography analysis. We observed that MS patients consistently showed decreased power within the alpha frequency band (8–13 Hz) as compared to the healthy group. We also derived a lesion matrix indicating the percentage of lesions for each tract in every patient. Using large‐scale brain modeling, the neural activity of each region was represented as a Stuart‐Landau oscillator operating in a regime showing damped oscillations, and the regions were coupled according to subject‐specific connectomes. We propose a linear formulation to the relationship between the conduction delays and the amount of structural damage in each white matter tract. Dependent upon the parameter , this function translates lesions into edge‐specific conduction delays (leading to shifts in the power spectra). Using deep neural density estimators, we found that the estimation of showed a strong correlation with the alpha peak in MEG recordings. The most probable inferred for each subject is inversely proportional to the observed peaks, while power peaks themselves do not correlate with total lesion volume. Furthermore, the estimated parameters were predictive (cross‐sectionally) of individual clinical disability. This study represents the initial exploration showcasing the location‐specific impact of myelin lesions on conduction delays, thereby enhancing the customization of models for individuals with multiple sclerosis.

16 April 2024 in Clinical Neurophysiology
Verified
Journal Article
Open access
APArianna Polverino
Arianna Polverino
ELEmahnuel Troisi Lopez
Emahnuel Troisi Lopez
MLMarianna Liparoti
Marianna Liparoti
RMRoberta Minino
Roberta Minino
ARAntonella Romano
Antonella Romano
PSPierpaolo Sorrentino
Pierpaolo Sorrentino
To test the hypothesis that patients affected by Amyotrophic Lateral Sclerosis (ALS) show an altered spatio-temporal spreading of neuronal avalanches in the brain, and that this may related to the clinical picture. We obtained the source-reconstructed magnetoencephalography (MEG) signals from thirty-six ALS patients and forty-two healthy controls. Then, we used the construct of the avalanche transition matrix (ATM) and the corresponding network parameter nodal strength to quantify the changes in each region, since this parameter provides key information about which brain regions are mostly involved in the spreading avalanches. ALS patients presented higher values of the nodal strength in both cortical and sub-cortical brain areas. This parameter correlated directly with disease duration. In this work, we provide a deeper characterization of neuronal avalanches propagation in ALS, describing their spatio-temporal trajectories and identifying the brain regions most likely to be involved in the process. This makes it possible to recognize the brain areas that take part in the pathogenic mechanisms of ALS. Furthermore, the nodal strength of the involved regions correlates directly with disease duration. Our results corroborate the clinical relevance of aperiodic, fast large-scale brain activity as a biomarker of microscopic changes induced by neurophysiological processes.

30 April 2024 in Children
Verified
Journal Article
Open access
PDF file
LCLorenzo Cipriano
Lorenzo Cipriano
RPRaffaele Piscopo
Raffaele Piscopo
CAChiara Aiello
Chiara Aiello
ANAntonio Novelli
Antonio Novelli
Achille IolasconAchille Iolascon
Achille Iolascon
CPCarmelo Piscopo
Carmelo Piscopo
Background: CACNA1C gene encodes the alpha 1 subunit of the CaV1.2 L-type Ca2+ channel. Pathogenic variants in this gene have been associated with cardiac rhythm disorders such as long QT syndrome, Brugada syndrome and Timothy syndrome. Recent evidence has suggested the possible association between CACNA1C mutations and neurologically-isolated (in absence of cardiac involvement) phenotypes in children, giving birth to a wider spectrum of CACNA1C-related clinical presentations. However, to date, little is known about the variety of both neurological and non-neurological signs/symptoms in the neurologically-predominant phenotypes. Methods and Results: We conducted a systematic review of neurologically-predominant presentations without cardiac conduction defects, associated with CACNA1C mutations. We also reported a novel de novo missense pathogenic variant in the CACNA1C gene of a children patient presenting with constructional, dressing and oro-buccal apraxia associated with behavioral abnormalities, mild intellectual disability, dental anomalies, gingival hyperplasia and mild musculoskeletal defects, without cardiac conduction defects. Conclusions: The present study highlights the importance of considering the investigation of the CACNA1C gene in children’s neurological isolated syndromes, and expands the phenotype of the CACNA1C related conditions. In addition, the present study highlights that, even in absence of cardiac conduction defects, nuanced clinical manifestations of the Timothy syndrome (e.g., dental and gingival defects) could be found. These findings suggest the high variable expressivity of the CACNA1C gene and remark that the absence of cardiac involvement should not mislead the diagnosis of a CACNA1C related disorder.